Bacterial Skin Infections

Primary Care - Clinics in Office Practice

Volumn 42, Issue 4, 2015, Pages 485-499

  Ibrahim, Fadi ^a   Khan, Tariq ^a   Pujalte, George G A ^b  

^a MOUNT SINAI HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Abscess; Cellulitis; Erysipelas; Impetigo; Methicillin resistant Staphylococcus aureus; Methicillin sensitive Staphylococcus aureus

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFALEXIN; CEFAZOLIN; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DICLOXACILLIN; DOXYCYCLINE; LINEZOLID; MINOCYCLINE; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PSEUDOMONIC ACID; TEDIZOLID; ANTIINFECTIVE AGENT;

ABSCESS; BACTERIAL SKIN DISEASE; CELLULITIS; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE PREDISPOSITION; EPIDERMIS; ERYSIPELAS; FOLLOW UP; HUMAN; HYGIENE; IMPETIGO; IMPETIGO BULLOSA; LYMPHADENOPATHY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS GROUP A; DIFFERENTIAL DIAGNOSIS; PRIMARY HEALTH CARE; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

ABSCESS; ANTI-BACTERIAL AGENTS; CELLULITIS; DIAGNOSIS, DIFFERENTIAL; ERYSIPELAS; HUMANS; IMPETIGO; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PHYSICAL EXAMINATION; PRIMARY HEALTH CARE; RISK FACTORS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 84961671449     PISSN: 00954543     EISSN: 1558299X     Source Type: Journal    
DOI: 10.1016/j.pop.2015.08.001     Document Type: Review

References (31)

1. Agency for Healthcare Research and Quality (AHRQ). Medical expenditure panel survey. Available at: . Accessed June 3, 2015. http://www.meps.ahrq.gov/mepsweb/.
2. Hartman-Adams H., Banvard C., Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician 2014, 90(4):229-235.
3. Dajani A.S., Ferrieri P., Wannamaker L.W. Natural history of impetigo. II. Etiologic agents and bacterial interactions. J Clin Invest 1972, 51:2863.
4. Hirschmann J.V. Impetigo: etiology and therapy. Curr Clin Top Infect Dis 2002, 22:42-51.
5. Stevens D.L., Bisno A.L., Chambers H.F., et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014, 59:147.
6. Rhody C. Bacterial infections of the skin. Prim Care 2000, 27:459-473.
7. Schachner L., Gonzalez A. Diagnosis and treatment of impetigo. J Am Acad Dermatol 1989, 20:132.
8. Dagan R. Impetigo in childhood: changing epidemiology and new treatments. Pediatr Ann 1993, 22:235-240.
9. Chira S., Miller L.G. Staphylococcus aureus is the most common identified cause of cellulitis: a systematic review. Epidemiol Infect 2010, 138(3):313-317.
10. Swartz M.N. Clinical practice. Cellulitis. N Engl J Med 2004, 350:904.
11. Pallin D.J., Binder W.D., Allen M.B., et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clin Infect Dis 2013, 56:1754.
12. Liu C., Bayer A., Cosgrove S.E., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant staphylococcus aureus infections in adults and children. Clin Infect Dis 2011, 52(3):e18-e35.
13. Dupuy A., Benchikhi H., Roujeau J.C., et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999, 318(7198):1591.
14. McNamara D.R., Tleyjeh I.M., Berbari E.F., et al. A predictive model of recurrent lower extremity cellulitis in a population-based cohort. Arch Intern Med 2007, 167(7):709.
15. Dan M., Heller K., Shapira I., et al. Incidence of erysipelas following venectomy for coronary artery bypass surgery. Infection 1987, 15(2):107.
16. Baddour L.M., Bisno A.L. Recurrent cellulitis after saphenous venectomy for coronary bypass surgery. Ann Intern Med 1982, 97(4):493.
17. Simon M.S., Cody R.L. Cellulitis after axillary lymph node dissection for carcinoma of the breast. Am J Med 1992, 93(5):543.
18. Perl B., Gottehrer N.P., Raveh D., et al. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis 1999, 29(6):1483.
19. Kielhofner M.A., Brown B., Dall L. Influence of underlying disease process on the utility of cellulitis needle aspirates. Arch Intern Med 1988, 148:2451.
20. Hook E.W., Hooton T.M., Horton C.A., et al. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986, 146:295.
21. Sachs M.K. The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med 1990, 150:1907.
22. Leppard B.J., Seal D.V., Colman G., et al. The value of bacteriology and serology in the diagnosis of cellulitis and erysipelas. Br J Dermatol 1985, 112:559.
23. Sigurdsson A.F., Gudmundsson S. The etiology of bacterial cellulitis as determined by fine-needle aspiration. Scand J Infect Dis 1989, 21:537.
24. Newell P.M., Norden C.W. Value of needle aspiration in bacteriologic diagnosis of cellulitis in adults. J Clin Microbiol 1988, 26:401.
25. Lebre C., Girard-Pipau F., Roujeau J.C., et al. Value of fine-needle aspiration in infectious cellulitis. Arch Dermatol 1996, 132:842.
26. Duvanel T., Auckenthaler R., Rohner P., et al. Quantitative cultures of biopsy specimens from cutaneous cellulitis. Arch Intern Med 1989, 149:293.
27. Bernard P., Plantin P., Roger H., et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol 1992, 127:155.
28. Martin J.M., Green M., Barbadora K.A., et al. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med 2002, 346:1200.
29. Treatment of community-associated MRSA infections. Med Lett Drugs Ther 2006, 48:13.
30. Miller L.G., Daum R.S., Creech C.B., et al. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med 2015, 372:1093.
31. Hepburn M.J., Dooley D.P., Skidmore P.J., et al. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004, 164:1669.